CVS pledges to stop shipping store-brand products that contain parabens and selected formaldehyde donors by the end of 2019, in an initiative that – for now – does not affect vendors. That could change, however, as CVS’ chemicals safety program is structured similarly to those in place at Target and Walmart, which are pursuing store-wide phase-outs of ingredients of concern.
Not to be outdone by leading big-box retailers, CVS Pharmacy announced April 20 that it will eliminate parabens and the most prevalent formaldehyde donors, as well as phthalates, from slews of its own branded beauty and personal-care products to “satisfy consumer expectations.”
The initiative will affect nearly 600 offerings under store brands CVS Health, Beauty 360, Essence of Beauty and Blade, according...
Create an account to read this article
Already a subscriber?
The Urban Wastewater Treatment Directive “in its current form, is at an end,” insists Pharma Deutschland CEO Jörg Wieczorek. To put the directive to bed once and for all, the association has applied for leave to intervene in the ongoing EU legal battle in its own right.
Based on advice from its advisory committees, the UK's Food Standards Agency is encouraging businesses to meet an acceptable daily intake of 10mg CBD per day and a safe upper limit of 0.07mg THC per day.
Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.
The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”
Joshi joins the parent company of Citeline, home of HBW Insight, to focus on AI, business harmonization and long-term growth.
A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.
Haleon described the opening of a new oral care R&D facility in the UK as a “major investment reflecting our commitment to advancing science and innovation.”
